Isabel Cunningham MD
Adjunct Associate Research Scientist, Division of Hematology Oncology, Columbia University College of Physicians and Surgeons, New York, New YorkWith broad experience in both academic oncology and clinical research, Dr. Cunningham provides a crucial bridge between community and academic medicine. Dr. Cunningham received her AB from Bryn Mawr College and her MD from Yale University School of Medicine. Her postgraduate training included a fellowship in hematology-oncology and bone marrow transplant at Memorial Sloan-Kettering Cancer Center. Dr. Cunningham has held academic positions at Memorial Sloan-Kettering and several other universities, and she is currently conducting research at Columbia University. She has published extensively and has been a reviewer for Blood, Bone Marrow Transplantation, Experimental Hematology, and Leukemia & Lymphoma.
Positions:
Adjunct Associate Research Scientist, Columbia University
Degrees:
Bryn Mawr College, AB
Yale University School of Medicine, MD
Postgraduate Training:
Resident, Internal Medicine, Presbyterian Hospital, New York
Fellow, Hematology/Oncology, Memorial Sloan-Kettering Cancer Center
Board Certifications:
Internal medicine
Hematology
Clinical Interests:
Hematologic malignancies
Extramedullary Leukemia
Disclosures
Dr. Cunningham does not have any financial disclosures.Recent Contributions to PracticeUpdate:
- Dr. Isabel Cunningham’s ESMO 2014 Recommendations in Hematological Malignancies
- Kinase-Activating Lesions Common in Ph-Like ALL
- Dr. Isabel Cunningham's ASCO 2014 LBA Pick for Leukemia
- Dr. Isabel Cunningham's 2014 ASCO Abstract Recommendations—Leukemia, Myelodysplastic Syndrome, and Myeloproliferative Disorder
- 2013 Top Stories in Oncology: Leukemia
- Dr. Isabel Cunningham's 2013 ASH Abstract Recommendations: Leukemia and Myelodysplastic Syndrome
- Obinutuzumab Approved as ‘Breakthrough’ Therapy for Chronic Lymphocytic Leukemia
- Multiple Infusions of Mesenchymal Stromal Cells Induce Sustained Remission in Children With Steroid-Refractory, Grade III-IV Acute Graft-Versus-Host Disease
- Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
- PD-L1 Expression Is Characteristic of a Subset of Aggressive B-Cell Lymphomas and Virus-Associated Malignancies